Cullinan Therapeutics has a robust T-cell engager pipeline, savvy management, and a strong cash position. Read more on what investors should know about the company.
On February 20, Barclays initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Overweight rating. The firm set a $1,350 price target on the stock.
Eric J. Larson is a community pharmacist, multi-store pharmacy owner in the Orlando area, and president of the Florida ...
NEW YORK, NY, UNITED STATES, February 19, 2026 /EINPresswire.com/ -- The New York Center for Cosmetic Dentistry (NYCCD) ...
This episode, titled Positioning Emerging Targeted Therapies in the Evolving IgA Nephropathy Treatment Paradigm, features ...
In recent months, Smile Hair Clinic has drawn renewed attention after receiving a certificate from TEMOS International ...
Just one day after Walgreens confirmed that it would lay off 159 workers at a distribution center in Texas, the company said ...
Dark, diamond-shaped spots in inner ear magnetic resonance imaging (MRI) scans are not always signs of pathological ...
The final, formatted version of the article will be published soon. Objective: This study aimed to investigate the horizontal positioning (HP) technique for the precise lateral insertion of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results